Search hospitals > Nevada > Reno

Center of Hope at Renown Medical Center

Claim this profile
Reno, Nevada 89502
Global Leader in Ovarian Cancer
Global Leader in Ovarian Tumors
Conducts research for Fallopian Tube Cancer
Conducts research for Cancer
Conducts research for Serous Cystadenocarcinoma
39 reported clinical trials
1 medical researcher
Photo of Center of Hope at Renown Medical Center in RenoPhoto of Center of Hope at Renown Medical Center in RenoPhoto of Center of Hope at Renown Medical Center in Reno

Summary

Center of Hope at Renown Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Ovarian Cancer, Ovarian Tumors, Fallopian Tube Cancer, Cancer, Serous Cystadenocarcinoma and other specialties. Center of Hope at Renown Medical Center is involved with conducting 39 clinical trials across 88 conditions. There are 1 research doctors associated with this hospital, such as Peter Lim.

Area of expertise

1Ovarian Cancer
Global Leader
Center of Hope at Renown Medical Center has run 24 trials for Ovarian Cancer. Some of their research focus areas include:
FRα positive
Stage III
Stage IV
2Ovarian Tumors
Global Leader
Center of Hope at Renown Medical Center has run 18 trials for Ovarian Tumors. Some of their research focus areas include:
FRα positive
Stage III
Stage IV

Top PIs

Clinical Trials running at Center of Hope at Renown Medical Center

Ovarian Cancer
Fallopian Tube Cancer
Ovarian Tumors
Endometrial Cancer
Cervical Cancer
Adenomyoepithelioma
Clear Cell Adenocarcinoma
Ovarian Carcinoma
Peritoneal Cancer
Peritoneal Carcinoma
Image of trial facility.

Olvi-Vec + Chemotherapy

for Ovarian Cancer

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

ONC-392 + Pembrolizumab

for Ovarian Cancer

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Recruiting2 awards Phase 212 criteria
Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Center of Hope at Renown Medical Center?
Center of Hope at Renown Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Ovarian Cancer, Ovarian Tumors, Fallopian Tube Cancer, Cancer, Serous Cystadenocarcinoma and other specialties. Center of Hope at Renown Medical Center is involved with conducting 39 clinical trials across 88 conditions. There are 1 research doctors associated with this hospital, such as Peter Lim.